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Highlights of the Asthma Summit 2009: Beyond the Guidelines
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Despite intense attention over the past 10–20 years,asthma still offers many potential new targets and ap-
proaches for improved treatment. Bronchospasm is the most
obvious target, which is amenable to treatment that relaxes
airway smooth muscle. Inflammation is the most emphasized
aspect of the disease and is used to direct maintenance
therapy at the underlying facets of asthma. However, emerg-
ing evidence indicates that inflammation itself represents a
more complex target than previously understood. The inflam-
mation of asthma is multicellular, and responses to treatment
can vary by cell type, so that treatment approaches should be
expanded to reflect these differences between individual pa-
tients. In addition, no currently available therapies address
injury repair, which is also multicellular and contributes to
progressive loss of lung function, a component of risk.
It is also apparent that personalized and flexible treat-
ments for patients with asthma are equally important. In fact,
many patients are already practicing their own “brand(s)” of
personalized and flexible therapy; as indicate by refill rates
for short-acting bronchodilators and maintenance medica-
tions. It is widely recognized that full compliance with
recommendations is only occasionally followed by many, if
not most, asthma sufferers. One important outcome of the
discussion at the Asthma Summit was that physicians who
treat patients with asthma should be willing to work with
patients to develop flexible options for treatment that main-
tain optimal asthma control. This approach requires patient
education, regular evaluation of asthma control, is best done
in conjunction with home peak flow monitoring, and requires
consideration of a range of treatment options that make sense
for the individual patient. Specific recommendations from the
Asthma Summit toward this goal include the following:
Y Individual phenotypes and/or clinical demographic
predictors should be taken into consideration when
determining appropriate treatment. The goal is to look
at specific patterns of symptoms and responses, plus
to determine a patient’s willingness to stay on regular
use of medications to create the most educated treat-
ment plan.
Y Asthma control needs to be monitored regularly. Control
questionnaires for patients, like the Asthma Control Test
(ACT), are helpful, as is the use of home peak flow
monitoring. Among the criteria we need to look at now
are how frequently patients exacerbate, need urgent care
visits, Emergency Department visits or hospitalizations,
or use prednisone bursts (as opposed to hospitalizations
or urgent care visits). The idea of monitoring symptom
control and pulmonary function in tandem to best man-
age patients is evolving as the best way to follow
patients.
Y Educating the patient is critical for success. The patient
needs to understand how much better their quality of life
can be when symptoms are not simply tolerated and no
longer interfere with daily activities. Despite 2 decades
of emphasizing airway inflammation, patients are still
unaware of the chronicity of asthma and the need for
ongoing treatment, even if the use of the treatment can
be flexible.
Y There is room for improvement in recognizing severe
disease. Use of SABA and prednisone bursts are both
important, and pharmacist involvement may be a good
mechanism to identify patients for specialist referral.
Pharmacists can also be quite helpful if refill rates are
shared with prescribing physicians as one way for com-
pliance to be estimated.
Y In terms of specialty treatment and referrals, establishing
good working relationships between the pulmonary and
the allergy communities is important.
There remains considerable variability in the practice of
asthma management, despite multiple reiterations of guide-
lines for managing asthma; and that variability is associated
with poor outcomes and high costs. It must be recognized that
although current guidelines provide an excellent reference to
the clinician seeking to better understand disease mechanisms
and evidence-based approaches to treatment, in practical
terms the hundreds of pages in these documents are not partic-
ularly useful, especially for the majority of general practice
physicians who see only a relatively few asthmatics. Shorter,
more focused, guidelines emphasizing updated standards of care
are still needed, with information presented from an operational
perspective. The experts at the Asthma Summit specifically
noted the following as missing from current guidelines:
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Y How lifestyle change can affect asthma outcomes should
be included, with specific examples. This is a topic that
is included in other guidelines for managing chronic
diseases (eg, cholesterol).
Y More information should be given on allergy manage-
ment including immunotherapy and its role in treating
asthma. This is a case where over-caution can be dam-
aging to practice, that is , limiting discussion because of
lack of evidence-based documentation in the literature
can preclude treatment that has been helpful for many
patients. It was agreed that immunotherapy is currently
guided by incomplete evidence; however, it was also
agreed that allergy assessment followed by appropriate
immunotherapy has helped many patients with allergic
asthma. Disregarding the potential importance of allergy
in the management of asthma can limit success and
commit the patient to recurrent disease that could oth-
erwise be improved.
Y Step down therapy needs to be better addressed. There are
seasonal patterns that drive increased treatment, but the
recommendations for step up, step down are not specifi-
cally discussed with regard to stepping down. One example
is viral infection, particularly the interplay with allergy as a
risk factor for having an asthma exacerbation. Both patients
and clinicians need to better understand what this means in
terms of day-to-day therapy.
In summary, despite multiple reiterations of asthma guide-
lines, control is still not achieved in the majority of asthma
patients, particularly those with more severe disease. On the
other hand, flexible dosing might be a much more appropriate
method to treat the milder or moderate asthmatic, and impressive
results from Europe suggest that this approach should be applied
within the United States as well. The time may be now to
consider the concept of a global, universal guideline for asthma
as a way forward to develop a flexible and personalized ap-
proach that will ultimately improve patient care.
WAO Journal • February 2010 Summary and Recommendations
© 2010 World Allergy Organization 43
